Want to see SE:SANION full AI Analyst Report?
Top Page
Saniona AB
(SANION)
Select Model
Select Model
Rating:68Neutral
Price Target:
kr12.50
▲(7.67% Upside)
Action:Reiterated
Date:10/14/26
The score is driven primarily by improved financial strength—strong recent profitability, positive cash generation, and a debt-free balance sheet—offset by pronounced revenue volatility that raises sustainability risk. Technical indicators remain a headwind due to a longer-term downtrend and negative MACD, while the low P/E provides supportive valuation if earnings persist.
Positive Factors
Strong Profitability
The sharp improvement to high net and EBIT margins demonstrates substantial current earnings power after prior losses. If profitability is supported by ongoing business activity, it can fund development internally, strengthen resilience, and provide Saniona greater flexibility in advancing its pipeline.
Negative Factors
Revenue Volatility
The sharp latest-TTM revenue decline creates uncertainty around the repeatability of current earnings and the visibility of future growth. In a biotech model that may include milestone or licensing revenue, uneven timing can make results less predictable and complicate sustained investment planning.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability
The sharp improvement to high net and EBIT margins demonstrates substantial current earnings power after prior losses. If profitability is supported by ongoing business activity, it can fund development internally, strengthen resilience, and provide Saniona greater flexibility in advancing its pipeline.
Read all positive factors
Saniona AB (SANION) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.54B
Dividend YieldN/A
Average Volume (3M)447.47K
Price to Earnings (P/E)8.3
Beta (1Y)0.39
Revenue Growth24.98%
EPS Growth-31.44%
CountrySE
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.34
Shares Outstanding138,030,140
10 Day Avg. Volume348,864
30 Day Avg. Volume447,472
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr267.00M
Saniona AB Business Overview & Revenue Model
Company Description
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system dis...
Saniona AB Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 424.56M | 434.40M | 334.67M | 16.84M | 15.28M | 10.48M |
| Gross Profit | 263.78M | 286.37M | 329.58M | 11.78M | 10.81M | 5.85M |
| EBITDA | 209.32M | 314.46M | 251.90M | -68.28M | -198.41M | -398.86M |
| Net Income | 183.53M | 284.67M | 188.71M | -95.81M | -245.36M | -410.90M |
Balance Sheet | ||||||
| Total Assets | 600.98M | 679.74M | 339.73M | 64.14M | 153.70M | 440.25M |
| Cash, Cash Equivalents and Short-Term Investments | 486.31M | 580.82M | 303.26M | 30.96M | 111.71M | 356.86M |
| Total Debt | 0.00 | 0.00 | 10.50M | 71.41M | 81.52M | 99.77M |
| Total Liabilities | 52.77M | 44.58M | 107.92M | 86.08M | 100.99M | 158.25M |
| Stockholders Equity | 548.22M | 635.16M | 231.82M | -21.94M | 52.71M | 282.00M |
Cash Flow | ||||||
| Free Cash Flow | 187.39M | 200.30M | 249.07M | -85.66M | -282.52M | -346.52M |
| Operating Cash Flow | 193.65M | 273.86M | 249.20M | -85.53M | -281.54M | -345.04M |
| Investing Cash Flow | -13.52M | -77.62M | -124.00K | -129.00K | 6.84M | 43.16M |
| Financing Cash Flow | -722.26K | 108.19M | 23.25M | -7.97M | -20.52M | 50.60M |
Saniona AB Technical Analysis
Positive
11.61
Price Trends
10.49
Positive
11.81
Negative
14.79
Negative
Market Momentum
0.28
Negative
62.54
Neutral
75.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SANION, the sentiment is Positive. The current price of 11.61 is above the 20-day moving average (MA) of 10.17, above the 50-day MA of 10.49, and below the 200-day MA of 14.79, indicating a neutral trend. The MACD of 0.28 indicates Negative momentum. The RSI at 62.54 is Neutral, neither overbought nor oversold. The STOCH value of 75.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SANION.
Saniona AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr40.76B | 59.09 | 15.54% | ― | <0.01% | -6.75% | |
69 Neutral | kr28.15B | 266.55 | 5.18% | 0.68% | -46.09% | -90.13% | |
68 Neutral | kr1.54B | 8.31 | 29.71% | ― | 24.98% | -31.44% | |
55 Neutral | kr4.00B | -5.01 | ― | ― | -3.57% | 8.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr882.54M | 42.87 | 65.99% | ― | ― | ― |
* Healthcare Sector Average
SE:SANION
Saniona AB
11.13
-4.65
-29.47%
SE:HNSA
Hansa Biopharma AB
39.34
8.14
26.09%
SE:MVIR
Medivir AB
1.55
1.01
187.04%
SE:CAMX
Camurus AB
673.00
48.50
7.77%
SE:ALZCUR
AlzeCure Pharma AB
6.40
4.47
232.29%
SE:BIOA.B
BioArctic AB Class B
317.20
26.13
8.98%
Saniona AB Corporate Events
Saniona Files IND for Rapid-Acting Depression Drug SAN2465
Oct 20, 2026
Saniona has filed an Investigational New Drug application with the U.S. Food and Drug Administration for SAN2465, an experimental therapy aimed at major depressive disorder, with a Phase 1 trial in healthy volunteers planned by year-end pending re...
Saniona advances SAN2465 as oral rapid-acting antidepressant with new preclinical data
Oct 13, 2026
Saniona has reported new preclinical data showing that its investigational drug SAN2465 significantly enhances hippocampal synaptic plasticity, a mechanism closely linked to learning, memory and antidepressant action. The compound, a GABA-A α...
Saniona maps out busy 2026 conference schedule to showcase neurology pipeline
Oct 8, 2026
Saniona plans an active presence at key investor, life science and scientific conferences through the remainder of 2026, including events in Stockholm, Lund, Cologne, Kolding, Rome, Washington, Vilnius and Denver. By presenting its programs and st...
Saniona Calls Extraordinary Meeting to Seek Fresh Issuance Mandate
Oct 7, 2026
Saniona AB has called an extraordinary shareholders’ meeting for 2 November 2026 in Malmö to address key corporate governance and financing matters. Shareholders must be registered with Euroclear Sweden AB by 23 October and submit notic...
Saniona readies IND filing for rapid-acting oral antidepressant SAN2465
Sep 24, 2026
Saniona has completed the toxicology and chemistry, manufacturing and controls studies for its experimental antidepressant SAN2465, securing the non-clinical and manufacturing data needed to support an Investigational New Drug application. The com...
Saniona Narrows R&D Focus as Losses Widen but Cash Position Strengthens
Aug 27, 2026
Saniona reported a sharp year-on-year decline in revenue and a significantly wider operating loss for the first half of 2026, even as its cash and cash equivalents rose to SEK 486.3 million, indicating a strengthened balance sheet despite deepenin...
Saniona Schedules Q2 Investor Call for 27 August 2026
Aug 20, 2026
Saniona AB has invited investors to join its Q2 investor call on 27 August 2026 at 11:00 CEST, where management will present quarterly results and a broader company update. The event, hosted via Redeye with a webcast replay available on the compan...
AstronauTx Takes Global Rights to Saniona Neurology Program as ATX0926 Moves Toward Clinic
Aug 10, 2026
Saniona and U.K.-based biotechnology firm AstronauTx have advanced their 2023 collaboration to a new stage, with AstronauTx exercising its option to acquire exclusive worldwide rights to a neurological disease program based on a novel ion channel ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.